Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Christopher F. O'Brien"'
Autor:
Christopher F. O'Brien, Jean-Pierre Lindenmayer, Cherian Verghese, Joshua Burke, Roland Jimenez, Grace S. Liang, Scott Siegert, Stephen R. Marder
Publikováno v:
CNS Spectrums. 26:345-353
BackgroundIndividuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be06c9351a4ddc2cd40f36f3c5701eaa
https://doi.org/10.1017/s109285292000108x
https://doi.org/10.1017/s109285292000108x
Autor:
Christopher F. O'Brien, Martha Sajatovic, Andrew J. Cutler, Mark Stacy, Christoph U. Correll, John M. Kane, Grace S. Liang
Publikováno v:
Mov Disord
Movement Disorders
Movement Disorders
Background A minimal clinically important difference has not been established for the Abnormal Involuntary Movement Scale in patients with tardive dyskinesia. Valbenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::617de9794fe56f22feb5339a001293bf
https://doi.org/10.1002/mds.27769
https://doi.org/10.1002/mds.27769
Publikováno v:
Reproductive Sciences. 25:1567-1576
Daily diary-based dysmenorrhea and nonmenstrual pelvic pain impact items were developed and validated to measure efficacy in endometriosis clinical trial settings. Items were developed across 3 stages of qualitative research, and their psychometric p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8e5fffe7ed576915d7f6c9faf7ea5a5
https://doi.org/10.1177/1933719118789509
https://doi.org/10.1177/1933719118789509
Publikováno v:
Drug Safety
Introduction Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. Objective Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c0ec19251e425379071dd40da318566
http://europepmc.org/articles/PMC5878201
http://europepmc.org/articles/PMC5878201
Autor:
Haig Bozigian, Gordon Loewen, Evan Smith, Dimitri E. Grigoriadis, Christopher F. O'Brien, Heather Skor
Publikováno v:
Drugs in R&D
Background Tetrabenazine (TBZ) activity is thought to result from four isomeric dihydrotetrabenazine (HTBZ) metabolites ([+]-α-HTBZ, [−]-α-HTBZ, [+]-β-HTBZ, [−]-β-HTBZ). Each isomer has a unique profile of vesicular monoamine transporter 2 (V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845369d5bd4fa809b25b75656d161a5e
http://europepmc.org/articles/PMC5629142
http://europepmc.org/articles/PMC5629142
Autor:
Joshua Burke, Roland Jimenez, Paul Michael Ramirez, Christopher F. O'Brien, Mary Ann Knesevich, Robert A. Hauser, Grace S. Liang, Stewart A. Factor, Stephen R. Marder
Publikováno v:
American Journal of Psychiatry. 174:476-484
Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics. Valbenazine (NBI-98854) is a novel, highly selective vesicular monoamine transporter 2 inhibitor that demonstrated favorable efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2812575bd07f69bd194050773422da9
https://doi.org/10.1176/appi.ajp.2017.16091037
https://doi.org/10.1176/appi.ajp.2017.16091037
Autor:
Christopher F. O'Brien, Joseph P. McEvoy, Grace S. Liang, Andrew J. Cutler, Christoph U. Correll, John M. Kane
Publikováno v:
The Journal of Clinical Psychiatry. 80
Background In the KINECT 3 (NCT02274558; October 2014 to September 2015) study, valbenazine efficacy in tardive dyskinesia (TD) was demonstrated based on mean changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) total score (sum of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae9d1f286d801dd2d365cb2b7bb61fa
https://doi.org/10.4088/jcp.18m12278
https://doi.org/10.4088/jcp.18m12278
Autor:
Adina F. Turcu, Tim Muth, Richard J. Auchus, Carole A. Ramm, Robert Farber, Dimitri E. Grigoriadis, Rosa Luo, David Madrigal, Christopher F. O'Brien, Joanna L. Spencer-Segal
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 101:1174-1180
Context: Treatment of 21-hydroxylase deficiency (21OHD) is difficult to optimize. Normalization of excessive ACTH and adrenal steroid production commonly requires supraphysiologic doses of glucocorticoids. Objectives: We evaluated the safety and tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cb36f01e908e5972a83b4fe35e0fcf5
https://doi.org/10.1210/jc.2015-3574
https://doi.org/10.1210/jc.2015-3574
Autor:
Julio C. Castro‐Gayol, Robert A. Hauser, Daniel Mandri, Joshua Burke, Stewart A. Factor, Christopher F. O'Brien, Roland Jimenez
Publikováno v:
Movement Disorders
Background Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abce43e1b94e713d6274b05f53f564fa
https://doi.org/10.1002/mds.26330
https://doi.org/10.1002/mds.26330
Autor:
Joshua Burke, Nándor Ács, Ping Jiang, Roland Jimenez, Elizabeth Garner, Christopher F. O'Brien, Kristof Chwalisz
Publikováno v:
Journal of Endometriosis and Pelvic Pain Disorders. 7:56-62
PurposeElagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosis-associated pain.MethodsIn th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2da62236cfb4fe207c733b6e235c748a
https://doi.org/10.5301/je.5000211
https://doi.org/10.5301/je.5000211